

## COMUNICAÇÃO ORAL 10

### *In vitro* neuro- and hepatotoxic profile of new psychoactive phenethylamines

Eva Gil-Martins<sup>1,2,3\*</sup>, Daniel Martins<sup>2</sup>, Catarina Fonseca<sup>1,2</sup>, Fernando Remião<sup>1,2</sup>, Fernanda Borges<sup>2</sup>, Renata Silva<sup>1,2,3</sup>

<sup>1</sup>Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

<sup>2</sup>UCIBIO - Applied Molecular Biosciences Unit, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.

<sup>3</sup>CIQUP, Research Center in Chemistry, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, 4169-007 Porto, Portugal.

\*✉ [evagilmartins@gmail.com](mailto:evagilmartins@gmail.com)

Doi: <https://doi.org/10.51126/revsalus.v4iSup.260>

#### Resumo

**Introduction:** Phenethylamine derivatives (PEAs) rank third in number of monitored substances by the EU Early Warning System [1]. However, since little or no information regarding their toxicology profile is available, they represent a constant danger to public health. **Objectives:** Thus, the main goal of this study was to evaluate the *in vitro* neurotoxic and hepatotoxic profile of three PEAs -mescaline, 2C-B and 2C-N - and their corresponding N-benzylphenethylamine (NBOMe) derivatives - mescaline-NBOMe, 25B-NBOMe and 25N-NBOMe - as well as explore the mechanistic pathways involved in their cytotoxicity. **Material and methods:** SH-SY5Y cells (dopaminergic phenotype) and HepG2 cells, representing two main target organs for these drugs – brain and liver, respectively –were used to perform all the *in vitro* experiments. Accordingly, the derivatives (0-2000  $\mu$ M) cytotoxicity was assessed 24 h after exposure, by the neutral red uptake assay. Their ability to produce free radicals was also measured, using the DCFH-DA fluorescent probe, and the impact of cytochrome P450 (CYP)-mediated metabolism on the compound's cytotoxicity was assessed by inhibiting different CYP isoforms, 24 h after exposure to the

compounds. Furthermore, after exposure of SH-SY5Y cells to the derivatives (0-500  $\mu$ M for 24 h), the intracellular reduced glutathione (GSH) levels were quantified, by the DTNB-reductase-recycling assay and the energy state was evaluated through the quantification of ATP intracellular levels (ATP bioluminescence assay). **Results:** All the tested PEAs (except mescaline) showed remarkable cytotoxic effects towards SH-SY5Y and HepG2 cells, with the addition of an N-benzyl moiety significantly increasing the observed cytotoxic effects. However, no ROS/RNS production was detected for any of the compounds in the tested conditions. Co-incubation with cytochrome P450 (CYP) inhibitors highlighted a potential role for these enzymes in the metabolism of the tested compounds, especially for CYP3A4 and CYP2D6. In SH-SY5Y cells, a concentration-dependent GSH depletion (for all the PEAs) and ATP decline (for all the PEAs except mescaline) was observed, being more pronounced for the NBOMe derivatives. **Conclusions:** In summary, the addition of a NBOMe moiety to the parent drug significantly increased its cytotoxic effects, and the inhibition of CYP3A4 and CYP2D6 emphasized CYP-mediated metabolism as a potential detoxification pathway for these drugs.

**Keywords:** neurotoxicity; hepatotoxicity; new psychoactive substances; phenethylamines.

#### References:

[1] European Monitoring Centre for Drugs and Drug Addiction. European Drug Report 2021: Trends and Developments, Publications Office of the European Union, Luxembourg, 2021.